Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Efficacy, Safety & Tolerability, and Pharmacokinetics of INS1007 Administered Daily for 24 Weeks in Non-Cystic Fibrosis Bronchiectasis - The Willow Study
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs INS 1007 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Willow study
- Sponsors Insmed
- 12 Jul 2017 Status changed from planning to not yet recruiting.
- 03 May 2017 According to an Insmed media release, company plans to initiate this trial in second half of 2017.
- 17 Oct 2016 New trial record